ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Study Recommends Longer Courses Of Chemotherapy For Bone Marrow Cancer

March 31, 2006

NCI Program: DOD’s TRICARE To Cover Patient Costs In NCI Prevention, Early detection Trials

September 10, 1999

House Members Express Support for Cancer Program

September 12, 1980

Construction Gets Extra $1 Million, Six Grants Okayed

May 29, 1981

Biostatisticians Write To Varmus Asking NCI To Investigate

July 23, 2010

Most of NCI’s Increase For Breast Cancer to Fund Grants: Broder

May 21, 1993